Gabelli Commercial [GCAD] vs Sagimet Biosciences [SGMT] Detailed Stock Comparison
Gabelli Commercial
NYSE
Loading...
Sagimet Biosciences
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Gabelli Commercial wins in 7 metrics, Sagimet Biosciences wins in 4 metrics, with 0 ties. Gabelli Commercial appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Gabelli Commercial | Sagimet Biosciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 0.39 | -5.03 | Sagimet Biosciences |
| Price-to-Book Ratio | 0.02 | 1.80 | Gabelli Commercial |
| Debt-to-Equity Ratio | 0.23 | 0.12 | Sagimet Biosciences |
| PEG Ratio | N/A | -0.18 | N/A |
| EV/EBITDA | -2.81 | -2.05 | Gabelli Commercial |
| Profit Margin (TTM) | 43.75% | 0.00% | Gabelli Commercial |
| Operating Margin (TTM) | N/A | 0.00% | N/A |
| Return on Equity | 7.54% | -37.89% | Gabelli Commercial |
| Return on Assets (TTM) | 4.11% | -25.61% | Gabelli Commercial |
| Free Cash Flow (TTM) | N/A | $-42.44M | N/A |
| 1-Year Return | 34.64% | 70.30% | Sagimet Biosciences |
| Price-to-Sales Ratio (TTM) | 0.00 | N/A | N/A |
| Enterprise Value | $-240.22B | $111.83M | Sagimet Biosciences |
| EV/Revenue Ratio | -0.45 | N/A | N/A |
| Gross Profit Margin (TTM) | 45.85% | N/A | N/A |
| Revenue per Share (TTM) | $1,470 | $0 | Gabelli Commercial |
| Earnings per Share (Diluted) | $115.58 | $-1.86 | Gabelli Commercial |
| Beta (Stock Volatility) | N/A | 3.27 | N/A |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Gabelli Commercial vs Sagimet Biosciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Gabelli Commercial | -0.37% | 1.79% | 6.45% | 10.35% | 50.33% | 36.06% |
| Sagimet Biosciences | 0.41% | 7.00% | 4.41% | -15.44% | 278.35% | 63.47% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Gabelli Commercial | 34.64% | 398.17% | 805.49% | 267.68% | 93.55% | 93.55% |
| Sagimet Biosciences | 70.30% | -53.95% | -53.95% | -53.95% | -53.95% | -53.95% |
News Based Sentiment: Gabelli Commercial vs Sagimet Biosciences
Gabelli Commercial
News based Sentiment: POSITIVE
Gabelli Funds demonstrated a strong commitment to the aerospace and defense sector throughout September 2025, highlighted by a major industry symposium, a new investment in Embraer, and positive analyst activity. These actions collectively signal a positive outlook for the industry and its potential for growth.
Sagimet Biosciences
News sentiment data is not available for Sagimet Biosciences at this time.
Performance & Financial Health Analysis: Gabelli Commercial vs Sagimet Biosciences
| Metric | GCAD | SGMT |
|---|---|---|
| Market Information | ||
| Market Cap | $0 | $249.31M |
| Market Cap Category | Micro cap | Micro cap |
| 10 Day Avg. Volume | 2,220 | 443,270 |
| 90 Day Avg. Volume | 1,630 | 471,207 |
| Last Close | $46.18 | $7.34 |
| 52 Week Range | $25.00 - $47.64 | $1.73 - $11.41 |
| % from 52W High | -3.07% | -35.67% |
| All-Time High | $47.64 (Oct 01, 2025) | $20.71 (Jan 22, 2024) |
| % from All-Time High | -3.06% | -64.56% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.02% | N/A |
| Quarterly Earnings Growth | N/A | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.44% | 0.00% |
| Operating Margin (TTM) | N/A | 0.00% |
| Return on Equity (TTM) | 0.08% | -0.38% |
| Debt to Equity (MRQ) | 0.23 | 0.12 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1,597.28 | $4.04 |
| Cash per Share (MRQ) | N/A | $3.86 |
| Operating Cash Flow (TTM) | $38.61B | $-54,230,000 |
| Levered Free Cash Flow (TTM) | $42.68B | $-35,545,376 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | $0.00 | N/A |
Valuation & Enterprise Metrics Analysis: Gabelli Commercial vs Sagimet Biosciences
| Metric | GCAD | SGMT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 0.39 | -5.03 |
| Forward P/E | N/A | -2.05 |
| PEG Ratio | N/A | -0.18 |
| Price to Sales (TTM) | 0.00 | N/A |
| Price to Book (MRQ) | 0.02 | 1.80 |
| Market Capitalization | ||
| Market Capitalization | $0 | $249.31M |
| Enterprise Value | $-240,215,000,000 | $111.83M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | -0.45 | N/A |
| Enterprise to EBITDA | -2.81 | -2.05 |
| Risk & Other Metrics | ||
| Beta | N/A | 3.27 |
| Book Value per Share (MRQ) | $1,597.28 | $4.04 |
Financial Statements Comparison: Gabelli Commercial vs Sagimet Biosciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GCAD | SGMT |
|---|---|---|
| Revenue/Sales | N/A | $0 |
| Cost of Goods Sold | N/A | N/A |
| Gross Profit | N/A | N/A |
| Research & Development | N/A | $15.34M |
| Operating Income (EBIT) | N/A | $-19.87M |
| EBITDA | N/A | $-19.87M |
| Pre-Tax Income | N/A | $-18.18M |
| Income Tax | N/A | N/A |
| Net Income (Profit) | N/A | $-18.18M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GCAD | SGMT |
|---|---|---|
| Cash & Equivalents | N/A | $64.72M |
| Total Current Assets | N/A | $146.07M |
| Total Current Liabilities | N/A | $7.18M |
| Long-Term Debt | N/A | N/A |
| Total Shareholders Equity | N/A | $138.99M |
| Retained Earnings | N/A | $-313.49M |
| Property, Plant & Equipment | N/A | $38,000 |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GCAD | SGMT |
|---|---|---|
| Operating Cash Flow | N/A | $-16.70M |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | $-14.54M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | GCAD | SGMT |
|---|---|---|
| Shares Short | N/A | 3.11M |
| Short Ratio | N/A | 5.61 |
| Short % of Float | N/A | 0.11% |
| Average Daily Volume (10 Day) | 2,220 | 443,270 |
| Average Daily Volume (90 Day) | 1,630 | 471,207 |
| Shares Outstanding | 367.21M | 32.20M |
| Float Shares | N/A | 22.63M |
| % Held by Insiders | N/A | 0.10% |
| % Held by Institutions | N/A | 0.29% |
Dividend Analysis & Yield Comparison: Gabelli Commercial vs Sagimet Biosciences
| Metric | GCAD | SGMT |
|---|---|---|
| Last 12-Month Dividend | $0.00 | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | $6.76 | N/A |
| 3-Year Avg Dividend Yield | 105.51% | N/A |
| 3-Year Total Dividends | $20.27 | N/A |
| Ex-Dividend Date | Dec 27, 2023 | N/A |